COMMUNIQUÉS West-GlobeNewswire

Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
09/05/2024
- Apnimed to Present Rationale and Design of LunAIRo Phase 3 Study for AD109 at the ATS 2024 International Conference - Topline Phase 3 Data Expected in Mid-2025 CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- [...]
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
09/05/2024
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt [...]
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
09/05/2024
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the [...]
ACELYRIN, INC. Announces Leadership Transition
09/05/2024
Mina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) Mpofu, M.D., MRCP, FRCP named Chief Medical Officer [...]
RAPT Therapeutics Reports First Quarter 2024 Financial Results
09/05/2024
Company maintains solid cash position of $141.6 million SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company [...]
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
09/05/2024
-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first [...]
Fulcrum Therapeutics to Participate in Upcoming May Conferences
09/05/2024
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
09/05/2024
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference
09/05/2024
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel [...]
AEON Biopharma Provides Update on Development Pipeline
09/05/2024
Includes two late-stage clinical programs and two early-stage clinical programs IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage [...]
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.
09/05/2024
Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented [...]
NEXGEL to Report First Quarter 2024 Financial Results on May 13th
09/05/2024
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over- [...]
Mounting Evidence that use of the Mental Health Collaborative Care Model is Associated with Reductions in Total Healthcare Costs
09/05/2024
Healthcare cost savings of 13% achieved under Collaborative Care Model versus treatment as usual WASHINGTON, May 09, 2024 (GLOBE NEWSWIRE) -- Lack of access to affordable and effective care for mental health and [...]
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09/05/2024
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. [...]
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
09/05/2024
Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024 Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025 [...]
Cronos Group Reports 2024 First Quarter Results
09/05/2024
Industry-leading balance sheet with $855 million in cash and cash equivalents Net revenue in Q1 2024 increased by 30% year-over-year to $25.3 million Spinach ® was top-3 in retail sales in Canada in the flower, edible, [...]
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
09/05/2024
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 [...]
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
09/05/2024
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today [...]
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
09/05/2024
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s [...]

Pages